• Welcome to Specialised Therapeutics
  • SE Asia (HQ)

    +65 3158 9940

  • Australia

    1300 798 820

  • New Zealand

    +64 9801 0299

small cell lung cancer - Specialised Therapeutics - Page 3

image_pdfimage_print
November 24, 2014
  • By stabioadmin
  • 0 Comments

Ariad and STA Announce Approval of ICLUSIG™ (ponatinib) in Australia

Cambridge, MA, and Melbourne, Australia, November 24, 2014: ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Specialised Therapeutics Australia Pty Ltd (STA), today announced the marketing approval of ICLUSIG™ (ponatinib) in Australia by the Therapeutic Goods Administration (TGA). The Australian Product Information for ICLUSIG states that it is indicated for the treatment of adult patients with: Chronic

Read More
April 28, 2014
  • By stabioadmin
  • 0 Comments

STA to License New Drug – ILUVIEN® – to Improve Vision in Patients with Diabetes-Induced Vision Loss

Melbourne, Australia and Atlanta, Georgia, 28 April 2014: Australian and New Zealand patients suffering from vision impairment due to a type of diabetes-induced eye disease will have access to a new treatment, following a license deal between Australian biopharmaceutical company Specialised Therapeutics Australia (STA) and Alimera Sciences. (NASDAQ: ALIM). The exclusive agreement enables STA to distribute

Read More
March 5, 2014
  • By stabioadmin
  • 0 Comments

STA Receives TGA Approval for ABRAXANE® in Combination with Gemcitabine for First-Line Treatment of Metastatic Pancreatic Cancer

Melbourne, Australia – March, 2014: Australian biopharmaceutical company Specialised Therapeutics Australia (STA) is pleased to announce that ABRAXANE® (nanoparticle albumin-bound paclitaxel) in combination with gemcitabine in now approved by the Therapeutic Goods Administration (TGA) for the first-line treatment of metastatic pancreatic cancer. The TGA approved indication is: ABRAXANE, in combination with gemcitabine, is indicated for the first-line

Read More